Product menu

OLDER MALE PATIENT SPEAKING WITH MALE DOCTOR

Recommendations

Learn more about recommendations for RSV vaccination in older adults.

The US Centers for Disease Control (CDC) Advisory Committee on Immunization Practices’ (ACIP) recommendations1

The ACIP recommends:

  • Adults aged ≥60 years may receive a single dose of RSV vaccine, using shared clinical decision-making

Vaccination timing1,2

  • Clinicians should offer RSV vaccination to adults 60 years and older using shared clinical decision-making
  • Optimally, vaccination should occur before the onset of the RSV season
  • For the 2023–2024 season, HCPs should continue to offer vaccination to eligible adults who remain unvaccinated

Vaccine co-administration1

  • ACIP considers co-administration of RSV vaccines with other adult vaccines during the same visit acceptable*†

* When administering more than one vaccine at the same visit, providers should separate injection sites by at least 1 inch if possible and consider administering vaccines that are associated with an enhanced local reaction in separate limbs.
† Administering RSV vaccine with one or more other vaccines at the same visit might increase local or systemic reactogenicity. There is data on co-administration of RSV and influenza vaccines. Data are lacking on the safety of co-administration with other vaccines that might be recommended for persons in this age group, such as COVID-19 vaccines; pneumococcal vaccines; adults tetanus, diphtheria, and pertussis vaccines; and the recombinant zoster vaccines. Given the lack of data on co-administration with other vaccines, ACIP recommends that decisions to co-administer should consider patient factors such as whether the patient is up to date with currently recommended vaccines, the feasibility of the patient returning for additional vaccine doses, risk for acquiring vaccine-preventable disease, vaccine reactogenicity profiles, and patient preferences.

The National Advisory Committee on Immunization (NACI) recommendations

NACI is reviewing the use of AREXVY. Recommendations and an update will follow.3
Click below for regular updates on NACI recommendations for RSV vaccination.

LEARN MORE

Other organizations that recommend RSV vaccination for adults aged 60+ years

American Diabetes Association (ADA)

  • The ADA recommends that adults with diabetes receive all vaccinations noted by ACIP, including RSV vaccination for those ≥60 years of age4

Global Initiative for Chronic Obstructive Lung Disease (GOLD)

  • GOLD strategy is now aligned with the ACIP recommendation for RSV vaccination for patients ≥60 years of age5

The Comité sur l’immunisation du Québec (CIQ)

Click below for information from the Protocole d'immunisation du Québec (PIQ) section on AREXVY.6

LEARN MORE

The Canadian Thoracic Society (CTS) and Association of Medical Microbiology and Infectious Disease (AMMI) joint message highlights the risk of respiratory viral illnesses in Canada.

The CTS and AMMI encourage patients to take simple actions to prevent the spread of RSV, including staying up to date on vaccinations.7

SPEECH BUBBLES ICON

Start the conversation about RSV risk with your patients aged 60+ years

Older adults aged ≥60 years may receive a single dose of RSV vaccine, using shared clinical decision-making.1

LEARN MORE

MAGNIFYING GLASS ICON

See AREXVY efficacy data

Efficacy of AREXVY against RSV-associated LRTD in adults 60 years and older was evaluated in Study AReSVi-006.8

LEARN MORE

References:

  1. Melgar M, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. Morb Mortal Wkly Rep 2023;72:793–801.
  2. Centers for Disease Control and Prevention. Healthcare providers: RSV vaccination for adults 60 years of age and older. Available at: https://www.cdc.gov/vaccines/vpd/rsv/hcp/older-adults.html#:~:text=Vaccine%20recommendations,-There%20are%20two&text=CDC%20recommends%20that%20adults%2060,RSV%20vaccination%20will%20be%20beneficial. Accessed February 21, 2024.
  3. Government of Canada. Respiratory syncytial virus (RSV): Canadian Immunization Guide. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html. Accessed January 26, 2024.
  4. American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes – 2024. Diabetes Care 2024:47(Suppl.1):S52–76.
  5. Global Initiative for Chronic Obstructive Lung Disease 2024 Report. Available at: https://goldcopd.org/wp-content/uploads/2024/01/GOLD-2024_v1.2-11Jan24_WMV-1.pdf. Accessed February 8, 2024.
  6. Protocole d'immunisation du Québec (PIQ). RSV: respiratory syncytial virus vaccine. Available at: https://www.msss.gouv.qc.ca/professionnels/vaccination/piq-vaccins/vrs-vaccin-contre-virus-respiratoire-syncytial/. Accessed February 21, 2024.
  7. Canadian Thoracic Society and Association of Medical Microbiology and Infectious Disease. Respiratory and medical microbiology & infectious disease societies encourage simple daily actions to prevent the spread of respiratory viral illnesses. Available at: https://cts-sct.ca/wp-content/uploads/2022/11/CTS-statement-virus-outbreak-Nov2022_Draft-AMMI-Canada_FINAL-1.pdf. Accessed on February 8, 2024.
  8. AREXVY Product Monograph. GlaxoSmithKline Inc.

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK Group of companies or its licensor.

104605 | 07/24

Open cookie banner
Hide cookie banner